Saturday 17 October 2026 Export SPRO’s income statement to Excel — free account

Spero Therapeutics, Inc.

Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 95.6%, EPS fell 433.3% and free cash flow grew 69.7%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

1.10 0.03 −2.65%

Follow SPRO

Alert me

Market cap: $65.8M
P/E: 7.9×
Fwd P/E: 4.2×
Dividend yield: —
F-score: 5/9
Altman Z: 1.04
Beneish M: −1.00
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.55

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	4	—	—	1	—	—	—	—	—

Insider Ownership 25.86%

Capital & Financial Ratios $m

Market Cap 65.80

Revenue 61.19

Net Income 7.38

Free Cash Flow 19.58

Net Debt (50.77)

Current Ratio 6.12

Debt/Equity 0.00

P/E ratio 7.86

Fwd P/E 4.21

P/S ratio 1.04

P/B ratio 1.44

Past 5Y EPS Growth —

This Y EPS Growth (486.67%)

Next Y EPS Growth (51.72%)

Next Y revenue growth (99.61%)

Next 5Y EPS Growth 18.80%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 19.14%

10-year low 10-year high

P/B against its own 10 years 36.70%

10-year low 10-year high

EV/Sales against its own 10 years 11.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	76	53	40	51
Receivables	51	52	25	0
Inventory	—	—	—	—
Other	—	—	—	—
	131	107	67	52

	2023	2024	2025	Q'26
Payables	1	7	1	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	37	49	9	8

Compound Annual Growth %

	10y	5y	3y
Sales	—	48.25%	7.68%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(14.87%)	(8.06%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	—	—	—	—
’25	6	14	5	41	67
’24	9	10	13	15	48
’23	2	3	25	74	104
’22	2	2	2	47	54
’21	7	5	3	3	18
’20	2	2	4	2	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	16	(5)	—	—	—
’25	(4)	(18)	17	(8)	(13)
’24	6	(19)	13	(23)	(23)
’23	(13)	(19)	16	(17)	(33)
’22	(28)	(23)	(1)	44	(8)
’21	(15)	(17)	(5)	(27)	(64)
’20	(23)	(25)	(21)	(16)	(86)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	16	(5)	—	—	—
’25	(4)	(18)	17	(8)	(13)
’24	6	(19)	13	(23)	(23)
’23	(13)	(19)	16	(17)	(33)
’22	(28)	(23)	(1)	44	(8)
’21	(15)	(17)	(5)	(27)	(64)
’20	(23)	(25)	(21)	(16)	(86)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.13)	(0.16)	—	—	—
’25	(0.25)	(0.03)	(0.13)	0.53	0.15
’24	(0.24)	(0.33)	(0.32)	(0.38)	(1.27)
’23	(0.25)	(0.23)	(0.06)	0.96	0.43
’22	(1.01)	(0.87)	(0.33)	0.55	(1.23)
’21	(0.66)	(0.63)	(0.70)	(0.90)	(2.91)
’20	(1.22)	(0.85)	(0.86)	(0.68)	(3.52)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	9.85	5.52	6.00	5.25	11.75	0.68	0.99	0.92	0.51	Analyst estimates 2026–2028 Powerpack
	High	—	15.40	19.00	14.48	23.64	22.24	16.30	2.04	1.89	3.22
People
People	Employees	29	35	41	57	89	146	35	46	32	25
	Revenue/emp, $m	0.01	0.06	0.10	0.32	0.10	0.13	1.53	2.26	1.50	2.67
Income, $m
Income, $m	Revenue	0	2	4	18	9	18	54	104	48	67
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(33)	(40)	(42)	(61)	(78)	(90)	(46)	25	(69)	9
	EBT margin, %	(9,743.58)	(2,015.46)	(1,050.48)	(335.73)	(839.01)	(491.65)	(86.74)	24.48	(142.91)	13.22
	Net income	(33)	(40)	(42)	(61)	(78)	(90)	(46)	23	(69)	9
	Depreciation	0	0	0	1	1	1	1	0	0	—
Per share, $
Per share, $	Revenue	1.07	0.77	0.25	1.00	0.42	0.59	1.42	1.97	0.89	1.19
	Earnings	(104.56)	(17.82)	(2.60)	(3.35)	(3.52)	(2.91)	(1.23)	0.43	(1.27)	0.15
	Cash flow	(92.76)	(15.12)	(2.48)	(2.75)	(3.84)	(2.08)	(0.21)	(0.63)	(0.43)	(0.23)
	Capex	(2.66)	(0.01)	(0.15)	(0.02)	(0.01)	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(95.42)	(15.13)	(2.63)	(2.77)	(3.84)	(2.08)	(0.21)	(0.63)	(0.43)	(0.23)
	Book value	20.37	32.84	7.24	4.11	5.90	2.86	2.02	2.03	0.85	1.05
	Shares, m	0	3	16	18	22	31	38	53	54	56
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.53	0.00	15.53
	P/S	0.00	15.87	24.81	9.63	46.52	27.09	1.22	0.77	1.16	1.95
	P/B	0.00	0.37	0.85	2.34	3.29	5.60	0.86	0.75	1.21	2.21
	EV/Sales	0.00	(28.24)	(4.29)	5.11	32.92	19.08	(0.82)	0.04	0.06	1.35
	EV/FCF	0.61	1.39	0.40	(1.84)	(3.57)	(5.41)	5.63	(0.11)	(0.12)	(7.13)
Cash, $m
Cash, $m	Operating cash flow	(29)	(39)	(40)	(50)	(86)	(64)	(8)	(33)	(23)	(13)
	Capex	(1)	0	(2)	0	0	0	—	—	—	—
	Free cash flow	(30)	(39)	(42)	(50)	(86)	(64)	(8)	(33)	(23)	(13)
Balance, $m
Balance, $m	Working capital	5	84	112	69	125	139	92	94	58	58
	Total debt	—	—	—	6	8	56	7	—	—	—
	Net debt	(10)	(87)	(115)	(82)	(127)	(146)	(109)	(76)	(53)	(40)
	Shareholders’ equity	6	85	116	75	132	88	76	107	46	59
Returns, %
Returns, %	ROA	(434.62)	(85.96)	(37.45)	(51.83)	(60.74)	(55.32)	(31.37)	14.85	(46.81)	9.55
	ROIC	0.00	0.00	(6,493.63)	0.00	(963.10)	0.00	0.00	43.93	0.00	21.04
	ROE	(169.30)	(258.18)	(41.49)	(63.99)	(76.31)	(81.48)	(56.53)	24.95	(89.62)	16.31

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CSBR Champions Oncology, Inc.	$66.7M	— (loss-making)	— (loss-making)	+8.84% (above 0%: growing)	n/m	−198.74% (below 0%: shrinking)	50.54%	(2.69%)	Compare
OSTX OS Therapies Incorporated	$66.0M	— (loss-making)	—	—	n/m	−134.43% (below 0%: shrinking)	—	0.00%	Compare
HYFT MindWalk Holdings Corp.	$66.0M	— (loss-making)	— (loss-making)	+19.37% (above 0%: growing)	n/m	+9.79% (above 0%: growing)	58.58%	(159.86%)	Compare
NMAD Nomad Power Solutions, Inc.	$65.9M	— (loss-making)	—	—	n/m	−230.63% (below 0%: shrinking)	—	0.00%	Compare
XBIT XBiotech Inc.	$65.9M	— (loss-making)	— (loss-making)	−93.33% (below 0%: shrinking)	n/m	+25.25% (above 0%: growing)	0.00%	0.00%	Compare
SPRO Spero Therapeutics, Inc.	$65.8M	7.9×	4.2×	−95.61% (below 0%: shrinking)	n/m	+69.73% (above 0%: growing)	100.00%	0.00%
VRCA Verrica Pharmaceuticals Inc.	$64.9M	— (loss-making)	— (loss-making)	−53.85% (below 0%: shrinking)	n/m	+7.63% (above 0%: growing)	85.02%	(223.42%)	Compare
CING Cingulate Inc.	$63.8M	— (loss-making)	—	—	n/m	−24.28% (below 0%: shrinking)	0.00%	0.00%	Compare
FBIO Fortress Biotech, Inc.	$63.7M	0.6×	1.1×	+14.04% (above 0%: growing)	n/m	−115.37% (below 0%: shrinking)	67.18%	(53.46%)	Compare
Median of peers	$65.9M	—	—	+8.84%	—	−69.82%	54.56%	(1.34%)

All 614 Biotechnology stocks →

Spero Therapeutics, Inc. (SPRO) key facts

Strength: Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024.
Spero Therapeutics, Inc. (SPRO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SPRO traded at $1.10, a market capitalization of $65.8 million.
Return on equity was 16.3% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.04 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.